Difference between revisions of "Denintuzumab mafodotin (SGN-CD19A)"
Jump to navigation
Jump to search
m (Jwarner moved page SGN-CD19A to Denintuzumab mafodotin (SGN-CD19A): Generic name available) |
m |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
| − | + | From the NCI Drug Dictionary: An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. | |
| − | =Preliminary studies= | + | ==Preliminary studies== |
# '''Abstract:''' Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) [http://meetinglibrary.asco.org/content/127120-144 link to original abstract] | # '''Abstract:''' Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) [http://meetinglibrary.asco.org/content/127120-144 link to original abstract] | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code name:''' SGN-CD19A | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
| − | + | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category: | + | [[Category:Anti-CD19 antibody-drug conjugates]] |
| − | + | [[Category:Microtubule inhibitors]] | |
| − | [[Category: | ||
| − | [[Category:Halted]] | + | [[Category:Halted drugs]] |
Latest revision as of 21:15, 30 June 2023
Mechanism of action
From the NCI Drug Dictionary: An immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the auristatin derivative monomethyl auristatin F (MMAF), with potential antineoplastic activity. Upon administration of denintuzumab mafodotin, the antibody moiety targets the cell surface antigen CD19, found on a number of B-cell-derived cancers.
Preliminary studies
- Abstract: Andres Forero-Torres, Craig Moskowitz, Ranjana H. Advani, Bijal D. Shah, Ana Kostic, Tina M. Albertson, Larissa Sandalic, Baiteng Zhao, Michelle A. Fanale. Interim analysis of a phase 1, open-label, dose-escalation study of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014 (suppl; abstr 8505) link to original abstract
Also known as
- Code name: SGN-CD19A